John S Rushing1, Leslie Appiah2, Alex J Polotsky2, Shona Murray2, Erin Foust2, Kathryn Hassell3, Cassandra Roeca2. 1. Department of Obstetrics and Gynecology, Anschutz Medical Campus, University of Colorado, 12631 E 17th Ave Ste B198-6, Aurora, CO, 80045-2529, USA. john.rushing@cuanschutz.edu. 2. Department of Obstetrics and Gynecology, Anschutz Medical Campus, University of Colorado, 12631 E 17th Ave Ste B198-6, Aurora, CO, 80045-2529, USA. 3. Department of Medicine, Anschutz Medical Campus, University of Colorado, Aurora, CO, USA.
Abstract
PURPOSE: To describe a case of a young woman who presented for fertility preservation and underwent ovarian stimulation with an etonogestrel implant in place. METHODS: A 24-year old, gravida 0, with an etonogestrel implant and newly diagnosed lower extremity sarcoma and DVT desiring oocyte cryopreservation prior to adjuvant chemotherapy and radiation. To avoid delay in her oncologic care and allow for continued use of contraception post-retrieval, the patient underwent controlled ovarian hyperstimulation (COH) without removal of the etonogestrel implant. RESULTS: Baseline labs included follicle-stimulating hormone 9 mIU/mL, luteinizing hormone 4.9 mIU/mL, estradiol 42 pg/mL, anti-Müllerian hormone 5.1 ng/mL, and antral follicle count greater than 40. The patient was placed on an antagonist protocol and stimulated with 125 IU Gonal-F and 75 IU Menopur. She received a total of 12 days of gonadotropin stimulation. On the day of trigger, her estradiol was 1472 pg/mL, lead follicle 21.5 mm with a total of 25 follicles measured > 12 mm. She was triggered with 5000 U hCG. She had a total of 23 oocytes retrieved, 17 of which were metaphase II and vitrified. CONCLUSIONS: COH and successful oocyte cryopreservation can be achieved in patients with an etonogestrel implant in situ without apparent detrimental effects to oocyte yield or maturity. Due to the etonogestrel implant's inhibitory effects on LH, it is recommended to use an hCG trigger for final oocyte maturation.
PURPOSE: To describe a case of a young woman who presented for fertility preservation and underwent ovarian stimulation with an etonogestrel implant in place. METHODS: A 24-year old, gravida 0, with an etonogestrel implant and newly diagnosed lower extremity sarcoma and DVT desiring oocyte cryopreservation prior to adjuvant chemotherapy and radiation. To avoid delay in her oncologic care and allow for continued use of contraception post-retrieval, the patient underwent controlled ovarian hyperstimulation (COH) without removal of the etonogestrel implant. RESULTS: Baseline labs included follicle-stimulating hormone 9 mIU/mL, luteinizing hormone 4.9 mIU/mL, estradiol 42 pg/mL, anti-Müllerian hormone 5.1 ng/mL, and antral follicle count greater than 40. The patient was placed on an antagonist protocol and stimulated with 125 IU Gonal-F and 75 IU Menopur. She received a total of 12 days of gonadotropin stimulation. On the day of trigger, her estradiol was 1472 pg/mL, lead follicle 21.5 mm with a total of 25 follicles measured > 12 mm. She was triggered with 5000 U hCG. She had a total of 23 oocytes retrieved, 17 of which were metaphase II and vitrified. CONCLUSIONS: COH and successful oocyte cryopreservation can be achieved in patients with an etonogestrel implant in situ without apparent detrimental effects to oocyte yield or maturity. Due to the etonogestrel implant's inhibitory effects on LH, it is recommended to use an hCG trigger for final oocyte maturation.
Authors: F A Peccatori; H A Azim; R Orecchia; H J Hoekstra; N Pavlidis; V Kesic; G Pentheroudakis Journal: Ann Oncol Date: 2013-06-27 Impact factor: 32.976
Authors: Kutluk Oktay; Brittany E Harvey; Ann H Partridge; Gwendolyn P Quinn; Joyce Reinecke; Hugh S Taylor; W Hamish Wallace; Erica T Wang; Alison W Loren Journal: J Clin Oncol Date: 2018-04-05 Impact factor: 44.544
Authors: Sarah Druckenmiller; Kara N Goldman; Patty A Labella; M Elizabeth Fino; Antonia Bazzocchi; Nicole Noyes Journal: Obstet Gynecol Date: 2016-03 Impact factor: 7.661
Authors: J Balasch; F Miró; I Burzaco; R Casamitjana; S Civico; J L Ballescá; B Puerto; J A Vanrell Journal: Hum Reprod Date: 1995-07 Impact factor: 6.918